Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.

Burton JH, Mazcko CN, LeBlanc AK, Covey JM, Ji JJ, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana SE, Weishaar K, London CA, Kisseberth WC, Krick E, Vail DM, Childress MO, Bryan JN, Barber LG, Ehrhart EJ, Kent MS, Fan TM, Kow KY, Northup N, Wilson-Robles H, Tomaszewski JE, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, Pommier Y.

Clin Cancer Res. 2018 Jul 30. pii: clincanres.1498.2018. doi: 10.1158/1078-0432.CCR-18-1498. [Epub ahead of print]

PMID:
30061364
2.

Targeting p53-dependent stem cell loss for intestinal chemoprotection.

Leibowitz BJ, Yang L, Wei L, Buchanan ME, Rachid M, Parise RA, Beumer JH, Eiseman JL, Schoen RE, Zhang L, Yu J.

Sci Transl Med. 2018 Feb 7;10(427). pii: eaam7610. doi: 10.1126/scitranslmed.aam7610.

PMID:
29437148
3.

Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma.

Christner S, Guo J, Parise RA, Ringeval M, Hoye AT, Wipf P, Epperly MW, Greenberger JS, Beumer JH, Eiseman JL.

J Pharm Biomed Anal. 2018 Feb 20;150:169-175. doi: 10.1016/j.jpba.2017.12.023. Epub 2017 Dec 12.

PMID:
29245086
4.

Estimation of body surface area in the musk shrew ( Suncus murinus): a small animal for testing chemotherapy-induced emesis.

Eiseman JL, Sciullo M, Wang H, Beumer JH, Horn CC.

Lab Anim. 2017 Oct;51(5):534-537. doi: 10.1177/0023677217695851. Epub 2017 Feb 26.

PMID:
28948895
5.

Evaluation of Silicon Phthalocyanine 4 Photodynamic Therapy Against Human Cervical Cancer Cells In Vitro and in Mice.

Gadzinski JA, Guo J, Philips BJ, Basse P, Craig EK, Bailey L, Comerci JT, Eiseman JL.

Adv Biol Chem. 2016 Dec;6(6):193-215. doi: 10.4236/abc.2016.66017. Epub 2016 Dec 30.

6.

LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.

Matsumoto J, Kiesel BF, Parise RA, Guo J, Taylor S, Huang M, Eiseman JL, Ivy SP, Kunos C, Chu E, Beumer JH.

J Pharm Biomed Anal. 2017 Nov 30;146:154-160. doi: 10.1016/j.jpba.2017.08.036. Epub 2017 Aug 31.

PMID:
28881312
7.

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

Kiesel BF, Parise RA, Guo J, Huryn DM, Johnston PA, Colombo R, Sen M, Grandis JR, Beumer JH, Eiseman JL.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1225-1235. Epub 2016 Oct 24.

8.

LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma.

Holleran JL, Eiseman JL, Parise RA, Kummar S, Beumer JH.

J Pharm Biomed Anal. 2016 Sep 10;129:359-366. doi: 10.1016/j.jpba.2016.07.027. Epub 2016 Jul 18.

9.

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.

Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, Beumer JH, Rubinstein L, Collins J, Tomaszewski J, Parchment R, Pommier Y, Doroshow JH.

Cancer Chemother Pharmacol. 2016 Jul;78(1):73-81. doi: 10.1007/s00280-016-2998-6. Epub 2016 May 11.

10.

Cancer-selective death of human breast cancer cells by leelamine is mediated by bax and bak activation.

Sehrawat A, Kim SH, Hahm ER, Arlotti JA, Eiseman J, Shiva SS, Rigatti LH, Singh SV.

Mol Carcinog. 2017 Feb;56(2):337-348. doi: 10.1002/mc.22497. Epub 2016 May 5.

11.

Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.

Wang H, Teriete P, Hu A, Raveendra-Panickar D, Pendelton K, Lazo JS, Eiseman J, Holien T, Misund K, Oliynyk G, Arsenian-Henriksson M, Cosford ND, Sundan A, Prochownik EV.

Oncotarget. 2015 Oct 20;6(32):32380-95. doi: 10.18632/oncotarget.6116.

12.

Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.

Holleran JL, Beumer JH, McCormick DL, Johnson WD, Newman EM, Doroshow JH, Kummar S, Covey JM, Davis M, Eiseman JL.

Cancer Chemother Pharmacol. 2015 Oct;76(4):803-11. doi: 10.1007/s00280-015-2857-x. Epub 2015 Sep 1.

13.

Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.

Teramachi J, Silbermann R, Yang P, Zhao W, Mohammad KS, Guo J, Anderson JL, Zhou D, Feng R, Myint KZ, Maertz N, Beumer JH, Eiseman JL, Windle JJ, Xie XQ, Roodman GD, Kurihara N.

Leukemia. 2016 Feb;30(2):390-8. doi: 10.1038/leu.2015.229. Epub 2015 Aug 19.

14.

Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).

Parise RA, Eiseman JL, Clausen DM, Kicielinski KP, Hershberger PA, Egorin MJ, Beumer JH.

Cancer Chemother Pharmacol. 2015 Sep;76(3):537-46. doi: 10.1007/s00280-015-2828-2. Epub 2015 Jul 21.

15.

In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction.

Christner SM, Clausen DM, Beumer JH, Parise RA, Guo J, Huang Y, Dömling AS, Eiseman JL.

Cancer Chemother Pharmacol. 2015 Aug;76(2):287-99. doi: 10.1007/s00280-015-2791-y. Epub 2015 Jun 7.

16.

Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs.

Muzzio M, Hu SC, Holleran JL, Parise RA, Eiseman JL, Yellow-Duke AE, Covey JM, Glaze ER, Engelke K, Egorin MJ, McCormick DL, Beumer JH.

Cancer Chemother Pharmacol. 2015 May;75(5):1015-23. doi: 10.1007/s00280-015-2722-y. Epub 2015 Mar 17.

17.

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.

Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH.

Cancer Chemother Pharmacol. 2015 Mar;75(3):537-46. doi: 10.1007/s00280-014-2674-7. Epub 2015 Jan 8.

18.

Group psychotherapy's impact on trust in veterans with PTSD: a pilot study.

Williams W, Graham DP, McCurry K, Sanders A, Eiseman J, Chiu PH, King-Casas B.

Bull Menninger Clin. 2014 Fall;78(4):335-48. doi: 10.1521/bumc.2014.78.4.335.

PMID:
25495436
19.

A phase i study of DMS612, a novel bifunctional alkylating agent.

Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE.

Clin Cancer Res. 2015 Feb 15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. Epub 2014 Dec 2.

20.

Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews.

Eiseman JL, Beumer JH, Rigatti LH, Strychor S, Meyers K, Dienel S, Horn CC.

Cancer Chemother Pharmacol. 2015 Jan;75(1):143-52. doi: 10.1007/s00280-014-2623-5. Epub 2014 Nov 15.

21.

Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.

Sen M, Paul K, Freilino ML, Li H, Li C, Johnson DE, Wang L, Eiseman J, Grandis JR.

Mol Med. 2014 Mar 18;20:46-56. doi: 10.2119/molmed.2013.00104.

22.

Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice.

Parise RA, Beumer JH, Clausen DM, Rigatti LH, Ziegler JA, Gasparetto M, Smith CA, Eiseman JL.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1195-204. doi: 10.1007/s00280-013-2296-5. Epub 2013 Sep 24.

23.

A cell-targeted photodynamic nanomedicine strategy for head and neck cancers.

Master A, Malamas A, Solanki R, Clausen DM, Eiseman JL, Sen Gupta A.

Mol Pharm. 2013 May 6;10(5):1988-97. doi: 10.1021/mp400007k. Epub 2013 Apr 24.

24.

In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts.

Guo J, Clausen DM, Beumer JH, Parise RA, Egorin MJ, Bravo-Altamirano K, Wipf P, Sharlow ER, Wang QJ, Eiseman JL.

Cancer Chemother Pharmacol. 2013 Feb;71(2):331-44. doi: 10.1007/s00280-012-2010-z. Epub 2012 Oct 30.

25.

Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.

Parise RA, Anyang BN, Eiseman JL, Egorin MJ, Covey JM, Beumer JH.

Cancer Chemother Pharmacol. 2013 Jan;71(1):73-83. doi: 10.1007/s00280-012-1980-1. Epub 2012 Oct 5.

26.

Inducible silencing of protein kinase D3 inhibits secretion of tumor-promoting factors in prostate cancer.

LaValle CR, Zhang L, Xu S, Eiseman JL, Wang QJ.

Mol Cancer Ther. 2012 Jul;11(7):1389-99. doi: 10.1158/1535-7163.MCT-11-0887. Epub 2012 Apr 24.

27.

Pharmacokinetics and tissue distribution of inositol hexaphosphate in C.B17 SCID mice bearing human breast cancer xenografts.

Eiseman J, Lan J, Guo J, Joseph E, Vucenik I.

Metabolism. 2011 Oct;60(10):1465-74. doi: 10.1016/j.metabol.2011.02.015. Epub 2011 Apr 12.

PMID:
21489580
28.

In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.

Clausen DM, Guo J, Parise RA, Beumer JH, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL.

J Pharmacol Exp Ther. 2010 Dec;335(3):715-27. doi: 10.1124/jpet.110.170555. Epub 2010 Aug 26.

29.

Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.

Zamboni WC, Eiseman JL, Strychor S, Rice PM, Joseph E, Zamboni BA, Donnelly MK, Shurer J, Parise RA, Tonda ME, Yu NY, Basse PH.

J Liposome Res. 2011 Mar;21(1):70-80. doi: 10.3109/08982101003754385. Epub 2010 Jun 9.

PMID:
20528623
30.

Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.

Beumer JH, Eiseman JL, Gilbert JA, Holleran JL, Yellow-Duke AE, Clausen DM, D'Argenio DZ, Ames MM, Hershberger PA, Parise RA, Bai L, Covey JM, Egorin MJ.

Cancer Chemother Pharmacol. 2011 Feb;67(2):421-30. doi: 10.1007/s00280-010-1337-6. Epub 2010 May 5.

31.

Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.

Holleran JL, Parise RA, Yellow-Duke AE, Egorin MJ, Eiseman JL, Covey JM, Beumer JH.

J Pharm Biomed Anal. 2010 Sep 5;52(5):714-20. doi: 10.1016/j.jpba.2010.02.020. Epub 2010 Feb 23.

32.

Pharmacokinetic modeling of motexafin gadolinium disposition in mouse tissues using optical pharmacokinetic system measurements.

Kanick SC, Eiseman JL, Parker RS.

Photodiagnosis Photodyn Ther. 2008 Dec;5(4):276-84. doi: 10.1016/j.pdpdt.2008.11.005. Epub 2009 Jan 23.

PMID:
19356671
33.

The relationship of phthalocyanine 4 (pc 4) concentrations measured noninvasively to outcome of pc 4 photodynamic therapy in mice.

Bai L, Guo J, Bontempo FA 3rd, Eiseman JL.

Photochem Photobiol. 2009 Jul-Aug;85(4):1011-9. doi: 10.1111/j.1751-1097.2009.00542.x. Epub 2009 Mar 20.

PMID:
19320848
34.

Improved synthesis of 6-epi-dictyostatin and antitumor efficacy in mice bearing MDA-MB231 human breast cancer xenografts.

Eiseman JL, Bai L, Jung WH, Moura-Letts G, Day BW, Curran DP.

J Med Chem. 2008 Nov 13;51(21):6650-3. doi: 10.1021/jm800979v. Epub 2008 Oct 8.

35.

Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.

Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM, Egorin MJ.

Clin Cancer Res. 2008 Jun 1;14(11):3529-35. doi: 10.1158/1078-0432.CCR-07-4885.

36.

Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.

Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL.

Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25. doi: 10.1007/s00280-008-0774-y. Epub 2008 May 29.

37.

Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice.

Zamboni WC, Jung LL, Strychor S, Joseph E, Zamboni BA, Fetterman SA, Sidone BJ, Burke TG, Curran DP, Eiseman JL.

Invest New Drugs. 2008 Oct;26(5):399-406. doi: 10.1007/s10637-007-9109-9. Epub 2008 Feb 2.

PMID:
18246299
38.

Nonlinear model predictive control for dosing daily anticancer agents using a novel saturating-rate cell-cycle model.

Florian JA Jr, Eiseman JL, Parker RS.

Comput Biol Med. 2008 Mar;38(3):339-47. doi: 10.1016/j.compbiomed.2007.12.003. Epub 2008 Jan 28.

PMID:
18222419
39.

Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma.

Parise RA, Beumer JH, Kangani CO, Holleran JL, Eiseman JL, Smith NF, Covey JM, Perrine SP, Egorin MJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Feb 1;862(1-2):168-74. Epub 2007 Dec 8.

40.

Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.

Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, Tonda ME, Yu NY, Engbers C, Eiseman JL.

Clin Cancer Res. 2007 Dec 1;13(23):7217-23.

41.

Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.

Beumer JH, Eiseman JL, Parise RA, Florian JA Jr, Joseph E, D'Argenio DZ, Parker RS, Kay B, Covey JM, Egorin MJ.

Cancer Chemother Pharmacol. 2008 Aug;62(3):457-64. Epub 2007 Nov 15.

42.

Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284).

Guo J, Parise RA, Joseph E, Lan J, Pan SS, Joo B, Egorin MJ, Wipf P, Lazo JS, Eiseman JL.

Anticancer Res. 2007 Sep-Oct;27(5A):3067-73.

43.

Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.

Zamboni WC, Strychor S, Joseph E, Parise RA, Egorin MJ, Eiseman JL.

Cancer Chemother Pharmacol. 2008 Aug;62(3):417-26. Epub 2007 Oct 24.

PMID:
17957368
44.

Noninvasive and nondestructive optical spectroscopic measurement of motexafin gadolinium in mouse tissues: comparison to high-performance liquid chromatography.

Kanick SC, Eiseman JL, Joseph E, Guo J, Parker RS.

J Photochem Photobiol B. 2007 Sep 25;88(2-3):90-104. Epub 2007 May 24.

PMID:
17604637
45.
46.
47.

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.

Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, Ivy SP, Potter DM, Chatta G, Zuhowski EG, Stoller RG, Naret C, Guo J, Belani CP.

Clin Cancer Res. 2007 Mar 15;13(6):1769-74.

48.

Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.

Beumer JH, Eiseman JL, Parise RA, Joseph E, Holleran JL, Covey JM, Egorin MJ.

Clin Cancer Res. 2006 Dec 15;12(24):7483-91. Epub 2006 Nov 30.

49.

A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice.

Beumer JH, Joseph E, Egorin MJ, Parker RS, D'argenio DZ, Covey JM, Eiseman JL.

Clin Cancer Res. 2006 Oct 1;12(19):5826-33.

50.

Accounting for quiescent cells in tumour growth and cancer treatment.

Florian JA Jr, Eiseman JL, Parker RS.

Syst Biol (Stevenage). 2005 Dec;152(4):185-92.

PMID:
16986259

Supplemental Content

Loading ...
Support Center